

CLINICAL EFFICACY OF A NEW FORMULATION

Containing BHA, Thiamidol, and Licochalcone A in Patients with Truncal Acne and Post-Inflammatory Hyperpigmentation

| Gallinger J | Kuhn A | Rauscher C | Seide C | Worthmann A-C | Drucks A | Keller J | Bürger A
| Beiersdorf AG, Hamburg, Germany

INTRODUCTION & OBJECTIVES

Body acne is a common condition that affects a significant proportion of individuals with facial acne. It can cause persistent scarring and has a higher impact on quality of life than facial acne alone.

Thiazolyl Resorcinol (Thiamidol) has emerged as an effective inhibitor of human tyrosinase that can reduce post-inflammatory hyperpigmentation (PIH). In this study, we investigated the clinical efficacy of a new formulation containing BHA (Salicylic Acid), Thiamidol, and anti-inflammatory Licochalcone A in patients with truncal acne and PIH.

MATERIALS AND METHODS

We conducted four studies to evaluate the efficacy of the new formulation. In clinical study 1, 38 female and male subjects with oily or combination skin type, presenting blemishes & post-acne marks on the body, applied the formulation once per day on the affected body areas over the course of 4 weeks. Self-grading of clear, unblemished complexion, expert grading on inflammatory lesion count, self-grading of visibility of post-acne marks and self-grading of redness reduction was evaluated. In clinical study 2, 27 female subjects underwent Corneometer measurement 24 hours after a single application to evaluate moisture. In study 3, a product in use study was conducted with results after 8 weeks of application, including Cardiff Acne disability index.


RESULTS

The results showed a 55% improvement in clear, unblemished complexion, a 33% reduction in inflammatory lesions, and a 67% reduction in the visibility of post-acne marks. Redness was reduced by 31%, and moisture increased significantly. The product in use study showed a 53% improvement in the

Cardiff Acne disability index, proving an improvement in quality of life. 99% of patients confirmed that they were now more confident to wear outfits that show off their skin.

Clear, unblemished complexion²


Self-grading on a scale from 1 to 10



Study 1: Clinical study with 38 participants (15-40 years, oily/combination skin) over 12 weeks.


Inflammatory lesions²

(count)




Visibility of post-acne marks²

Self-grading on a scale from 1 to 10



Study 1: Clinical study with 38 participants (15-40 years, oily/combination skin) over 12 weeks. Example shown, results may vary.

CADI (Cardiff Acne related disability index)



Product use study with 160 participants (15-40 years, acne-prone skin) over 8 weeks.

CONCLUSION

The new formulation containing BHA, Thiamidol, and anti inflammatory Licochalcone A is an effective treatment for truncal acne and PIH. It significantly improves the appearance of the skin, reduces inflammation, and increases moisture. The formulation also has antimicrobial properties and improves quality of life. The results of this study suggest that this formulation can be a promising treatment option for patients suffering from body acne.



Study 4: Clinical study with 38 participants (15-40 years, oily/combination skin) over 12 weeks. Example shown, results may vary.